Breast cancer data analyzed by race/ethnic groups to identify differences in diagnosis, prognosis
the ONA take:
According to a new study published in the journal JAMA, researchers from Women's College Hospital in Toronto, Ontario, Canada, have found that race and ethnicity may play a role in the timing of breast cancer diagnosis and the prognosis of the woman's disease.
For the study, researchers sought to investigate whether biological differences in tumor aggressiveness affect differences in early-stage breast cancer diagnosis by ethnicity and race.
They identified 373,563 women diagnosed with stage 1 breast cancer from the Surveillance, Epidemiology and End Results (SEER) database between 2004 and 2011. Women were followed for an average of 40.6 months. Researchers then categorized those women based on race and ethnicity and assessed the biological aggressiveness of the tumors.
They also assessed timing of diagnosis and prognosis based on race/ethnic group. Results showed that Japanese women were more likely to be diagnosed with stage 1 breast cancer than non-Hispanic white women.
In addition, black and South Asian women were more likely to be diagnosed at a later stage than non-Hispanic white women, and black women were more likely to die from stage 1 disease than non-Hispanic white women and South Asian women. Black women were also more likely to die from small-sized tumors than non-Hispanic white women.
When analyzing biological differences in tumor aggressiveness, they found that black women with small-sized tumors were more likely to have triple-negative disease and to present with local and distant metastases than non-Hispanic white women. The researchers note that socioeconomic factors and access to health care may also play a role.
Race and ethnicity may play a role in the timing of breast cancer diagnosis and the prognosis of the woman's disease.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
- Nonadherence to Posttreatment Imaging Follow-up Common Among Breast Cancer Survivors
- HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|